Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. April 2026 07:00 ET | Quelle: Incyclix Bio

Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors

RESEARCH TRIANGLE PARK, N.C., April 08, 2026 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for...
22. September 2025 09:00 ET | Quelle: Incyclix Bio

Fierce Biotech names Incyclix Bio a “Fierce 15” Biotech Company of 2025

RESEARCH TRIANGLE PARK, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, today announced that Fierce Biotech has named it as one of 2025’s Fierce 15 biotechnology companies, designating...
11. März 2019 10:00 ET | Quelle: ActivX Biosciences

ActivX Biosciences reports key findings that could impact the use of clinically approved CDK4/6 inhibitors in the treatment of cancer patients

LA JOLLA, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- ActivX Biosciences, Inc., a wholly-owned subsidiary of Kyorin Pharmaceutical Co., Ltd. (Tokyo), announces a report published in a high profile,...